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longer used because of accelerated biodegradation.
Unmodified allografts, despite low immunogenicity, are
similarly no longer used because of rejection.
Pretreatment of allografts or even xenografts with chemi-
cal agents, freezing techniques, or lyophilization can result
in biological materials that can retain durable structure
and function. Experience with aldehyde processing (tan-
ning) has provided unique insights into the usefulness, lia-
bilities, and challenges that accompany its deployment for
biologically derived materials. The pioneering work of
Rosenberg et al1,2 focused on the ability of aldehyde pro-
cessing to provide strength, flexibility, ease, and reliability
of use and to produce a material devoid of antigenicity and
shelf-available and sterile for implantation. Many of these
objectives were indeed achieved, but some, immunogenic-
ity and biodegradation in particular, required additional
effort during the past two decades for resolution. Our
The quest for a suitable alternative to the autologous
saphenous vein has preoccupied surgeons, engineers, and
textile scientists for decades. Some of these alternatives
have proved more useful than others, and many have been
abandoned. For example, unmodified heterografts are no
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Purpose: Biological material has been used as an alternative to autogenous vein since the first lower extremity revascu-
larization procedures were performed. Our experience with glutaraldehyde-tanned human umbilical cord vein graft
(UVg), which spanned a period of 28 years, forms the basis of this report, with an emphasis on comparative results
between the two decades from 1975 to 1985 and from 1990 to 2000.
Methods: Between 1990 and 2000, 283 lower extremity bypass grafting procedures were performed in 230 patients (264
limbs), with UVg used as the predominant, or sole, graft material. Our experience with 907 reconstructions in the
decade from 1975 to 1985 has been previously documented and now serves as a baseline comparison with the past
decade of experience with UVg. Each reconstruction was classified on the basis of the distal anastomotic site with or
without distal arteriovenous fistulas (dAVFs). The primary and secondary graft patency rates were determined for each
category as was cumulative palliation, which combines the end points of graft failure, amputation, and death.
Results: The results from the second decade (1990 to 2000) showed a continuation of improving patency rates for UVg
grafts in lower extremity revascularization. Comparison results of complications showed no changes in the low inci-
dence rates of infection, stenosis, dissection, and pseudoaneurysm. The original series results showed a 2.9% require-
ment for aneurysm surgery, with an incidence rate of biodegradation of 57% (36% aneurysms, 21% dilation), whereas
the current series results have shown no aneurysms to date. The comparative 6-year secondary patency rates for past
and current popliteal and crural bypass grafts (with or without dAVF) were: popliteal, 53% versus 67%, P < .05; and
crural, 26% without dAVF versus 47% with dAVF, P < .05. The limb salvage rates for the two series at 6 years showed
no significant changes between the decades and the types of bypass grafts. Thrombolysis was performed during the
decade from 1990 to 2000 in 27 UVg cases, with lysis achieved in 23 cases (85%) and limb salvage achieved in 20 cases
(74%). Since 1996, associated endovascular procedures (fluoroscopy, angioplasty) have assumed increasing importance
in the reduction of perioperative graft closure and in the enhancement of patency.
Conclusion: Our continuing experience with UVg confirms that favorable results can be obtained with this biologic
alternative to autologous vein for lower limb revascularization. Concern regarding biodegradation and aneurysm for-
mation even after 5 years are unfounded at this time. Improved patency and limb salvage rates can be achieved in con-
cert with lower nonthrombotic failure rates, increasing performance of associated endovascular procedures, use of
tourniquets, and the addition of dAVF for crural bypass grafting. Prospective randomized studies are still necessary for
the assessment of the comparative role of all graft materials, a project that continues to evade our specialty.
(J Vasc Surg 2002;35:64-71.)
original experimental work with human umbilical vein
began in the early 1970s.3-5 The clinical trials were initi-
ated in 1974 with the glutaraldehyde-tanned umbilical
vein graft (UVg).6-8 Earlier negative experience with
bovine heterograft, which was dialdehyde-starch
processed,9 was a key factor in the doubt and skepticism
within the vascular community, despite randomized
prospective study results that showed satisfactory perfor-
mance of UVg as an alternative to autologous vein.10-12 In
general, many reports that deal with vascular grafts are
characterized, at best, with medium-term follow-up stud-
ies and are often devalued with inappropriate case selec-
tion, characterization, and clinical/pathologic staging.
Established guidelines now can provide a suitable basis on
which to perform appropriate prospective randomized
studies.13 The studies cited previously and the recent pub-
lication of Johnson and Lee14 of similar work performed
in the 1980s are, amazingly, the only peer-reviewed publi-
cations that compare more than one alternative with the
saphenous vein for lower limb revascularization. This
report documents the continuous experience by a single
group during a period of almost three decades in which a
single graft was studied in detail. In 1988, the senior
author and colleagues reported their 10-year experience
(1975 to 1985) with 907 UVg bypass grafts.15 This report
continues that experience and documents for comparative
purposes the decade from 1990 to 2000, which reflects
modifications that have been made to the graft and to our
enlarging experience.
PATIENTS AND METHODS
Between 1990 and 2000, 283 lower extremity bypass
grafting procedures were performed in 230 patients (264
limbs), with UVg used as the predominant, or sole, graft
material. These grafts generally originated at the femoral
artery level and terminated distally (as noted subse-
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quently) as a single graft. In 12 patients, autologous vein
was used in the creation of a sequential addition to
another remote vessel (eg, a sequential jump to a plantar
artery from a femoral peroneal UVg graft). There were no
composite configurations. Proximal anastomoses were
generally at the common femoral artery level. Because suf-
ficient length of material is always available, we tend to
avoid the use of the superficial femoral artery. Proximal
superficial femoral artery was used, however, in 14 cases
because of obesity. In instances of desmoplasia on the basis
of prior surgery, we prefer the use of the external and even
the common iliac artery, which accounted for 22 cases.
Our experience with 907 reconstructions in the decade
from 1975 to 1985 has been previously documented15
and now serves as a baseline comparison with the most
recent decade of experience with UVg. Fig 1 details the
numbers and types of bypass grafts that were performed
with UVg since 1975, with new data from the decade
from 1990 to 2000 summarized in Figs 2 and 3. As in the
earlier series, 88% of all the bypass grafts were below the
knee. Almost 60% were infrapopliteal grafts, an increase of
10% from the first decade. The demographics and risk fac-
tors are depicted in Table I and generally parallel our prior
experience and that of others. The male to female ratio
was 1.6 to 1, which was slightly less than the 2 to 1 ratio
that was noted in the first decade. The mean age was 69 ±
10 years, with a range of 49 to 87 years. Although wide
ranges for these risk factors occur within the various sub-
group reconstructions, there is clearly an increasing impact
of these factors with progressive obliterative disease from
the popliteal arteries to the peroneal arteries.
Lower limb bypass grafting surgery had been previ-
ously performed in 120 limbs (42%). Two additional
patients (0.8%) had failed superficial femoral artery and
superficial femoral artery plus popliteal artery angioplasty
procedures. Prior inflow procedures that consisted of aor-
Fig 1. Numbers and types of umbilical vein grafts implanted
from 1975 to 2000. Grafts implanted since 1990 were prepared
by new manufacturer. Each bar since 1986 represents total umbil-
ical vein bypass grafts for that year. Bottom numbers are
popliteals, and above those are crurals. See Dardik et al15 for
details for first decade. UV, Umbilical vein graft; Pop, popliteal.
Fig 2. Type, number, and percentage of distal anastomoses of
umbilical vein grafts for 1990 to 2000. Shift of 10% occurred
from popliteals to crurals in comparison of two decades. n indi-
cates the numbers of bypass grafts. UV, Umbilical vein graft; pop,
popliteal; BK, below-knee; AK, above-knee; AT, arterior tibial;
PT, posterior tibial.
tic and extra-anatomic reconstructions, profundoplasties,
and transluminal angioplasties had been performed in 46
instances (16%). In this study, synchronous inflow recon-
struction in the form of angioplasty and stenting was per-
formed in only 10 cases during the last 5 years, which
adjusts to 5.6% of the total number of bypass grafting pro-
cedures performed during this time interval.
Indications and operative technique. The indica-
tions for surgery are made on the basis of the clinical man-
ifestations of the various patterns of occlusive
atherosclerosis (Fig 3). The main clinical categories for
case selection were: 1, gangrene; 2, critical ischemia (rest
pain, nonhealing ulcers, and focal gangrenous lesions);
and 3, disabling claudication. Claudication was the indica-
tion in 10% of the cases, with the remainder being equally
divided between limb salvage for gangrene or critical
ischemia. There was one elective case that was performed
for the indication of aneurysm of the femoral popliteal sys-
tem. At our institution, 1091 lower limb bypass grafting
procedures were performed during the decade from 1990
to 2000 (range, 72 to 140; mean, 109). During this time,
we used as few as 14 UVgs (in 1 year) and as many as 45
during 1998 (Table I). The percentage use of UVgs varies
from 20% to 30% per annum.
The indications for the use of UVg are primarily on
the basis of the absence or inadequacy of the saphenous
vein. In a few instances, the need to facilitate and shorten
the time of bypass grafting procedures in individuals with
multiple risk factors who would otherwise need a major
limb amputation similarly led to the choice of UVg.
The technical requirements for the use of UVg have
been previously documented, including the use of the
tourniquet, the distal arteriovenous fistula (dAVF) for
crural reconstructions, and our intraoperative and postop-
erative anticoagulation therapy protocol.16-19 Some of the
most important technical points relate to the gentle han-
dling of the graft, the avoidance of standard clamps, the
proper trimming of the ends in preparing anastomosis,
full-thickness suture bites, and generally, the performance
of the distal anastomosis first. It is preferable that this
anastomosis be performed with tourniquet control, with
the use of a dAVF for tibial and peroneal reconstructions,
and then, after completion of the distal anastomosis and
removal of the tourniquet, with the passing of the graft
through a tunneler in preparation for the proximal anasto-
mosis. We use interrupted sutures at the toe and the heel
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of tibial and peroneal bypass grafts and continuous tech-
nique elsewhere, including “parachute” anastomosis at the
femoral level and most importantly for iliac anastomosis.
After surgery, the patients undergo heparin therapy during
their hospital stay and are converted during this time to
undergo Coumadin therapy. The use of clopidogrel bisul-
fate is being investigated.
Data collection and analysis. The data for all the
bypass grafting procedures from 1975 to 2000 were col-
lected as a prospective study with a defined data collection
sheet. Analysis, including the life tables, was performed with
a computer program that we designed and enhanced during
the past decade with the Excel program (Microsoft, Seattle,
Wash).20 All the bypass grafts were classified on the basis of
distal anastomotic site with or without dAVF. Unlike the
first decade series, in the current decade, bypass graft proce-
dures to the trifurcation and sequential reconstructions were
rarely performed and were categorized in relationship to the
dominant vessel where the anastomosis was performed with
its appropriate runoff. Clinical and noninvasive vascular fol-
low-up studies were carried out at intervals of 3 to 6
months. These studies consisted of ankle-brachial indices,
duplex scan studies with documentation of morphology and
hemodynamic data, and, if appropriate, pulse volume
recordings (without graft compression). The availability of
duplex scan sonography has significantly altered our moni-
toring protocol. Completion sonographic scanning is rou-
tine and includes the entire length of the graft. Graft
diameter greater than 10 millimeters was considered
“dilated” and “aneurysmal” if the pathologic dilatation was
localized, segmental, or clearly enlarged in relation to the
adjacent vascular structure. Completion angiographic scan-
ning is performed selectively. Duplex scan sonography is
readily accepted by the patient and enables an earlier deter-
mination of potential “failing” bypass grafts. The indications
for revision of grafts that were deemed to be failing were
increased peak systolic velocities (>250 cm/s), loss of the
reversed flow component in diastole, and a ratio of more
than 3.0 (velocity at stenosis/velocity proximal to stenosis).
Complications were tabulated, including nonthrom-
botic causes. This category consists of cases that needed
amputation with patent grafts because of progressive gan-
grene of the foot or continued wound infection that failed
to respond to increased perfusion.
Graft patency and limb salvage rates are expressed with
the actuarial life table method.21 The log-rank test was
Table I. Patient and graft implant data for 1990 to 2000
N Age (range) Male:female Prior bypass 
Group No. of grafts in years ratio Diabetes Smokers grafting
Popliteal above-knee 34 (12%) 72 (55 to 87) 2.2:1 22% 38% 26%
Popliteal below-knee 81 (29%) 70 (49 to 87) 1.3:1 46% 32% 38%
Posterior tibial 55 (19%) 67 (53 to 84) 2.6:1 48% 43% 45%
Anterior tibial 47 (17%) 67 (57 to 85) 1:1.8 53% 52% 49%
Peroneal 66 (29%) 69 (61 to 88) 2.9:1 70% 62% 48%
Total 283 (100%) 69 (49 to 88) 1.6:1 48% 45% 42%
used to test differences between groups. In addition to the
documentation of primary and secondary graft patency
rates, the assisted patency rates and the cumulative actual
palliation rates also were analyzed, the latter combining
the endpoints of graft failure, amputation, and death.22
RESULTS
The numbers of UVg cases, the indications, and the
types of procedures for surgical revascularization are sum-
marized in Figs 1 to 3. The need to secure limb salvage or
reverse progressive tissue loss accounted for 89% of the
cases. Most of the patients in this study (87%) underwent
a single operation. Repetitive ipsilateral procedures were
required in 11 patients, which accounted for a total of 15
additional ipsilateral grafts (5%). There were 19 contralat-
eral procedures (7%). These results compare with the
authors’ previous findings during the first decade of expe-
rience with UVg in which a single procedure was possible
in 78% of the patients and contralateral procedures in less
than 12%.15 Symmetry of procedures also was once again
noted in this series; that is, the type of contralateral recon-
struction eventually required was similar to that per-
formed in the original (ipsilateral) limb.
Most of the cases in this series were infragenicular
(88%), with a greater number of crural reconstructions
(59%) as compared with popliteal reconstructions (41%;
Fig 2). This decade has shown a shift of approximately
10% of the below-knee popliteals to crural reconstruc-
tions. Most of the latter reconstructions were to the per-
oneal arteries (41%). The percentage of above-knee
popliteal reconstructions in the current decade (12%) was
essentially identical to that of the first decade (11%). Eight
of the 34 above-knee bypass grafting procedures (24%)
were to isolated popliteal segments as compared with nine
of the 81 below-knee popliteal bypass grafting procedures
(11%). These figures are also similar to the authors’ prior
experience in which bypass grafting procedures to above-
knee and below-knee isolated popliteal segments repre-
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sented 34% and 15%, respectively, of the total bypass graft-
ing procedures performed to each of these sites.
Cumulative functions. Cumulative graft patency and
limb salvage rates are depicted in Figs 4 to 6, with accom-
panying data in Table II. There were no significant differ-
ences between the primary, primary assisted (not
depicted), and secondary patency rates of a particular
reconstruction. Secondary patency rates for popliteal and
crural reconstructions at 5 years for the decade from 1990
to 2000 were 71% and 56% (with dAVF), respectively.
These figures were 11% and 6% more than their respective
primary patency rates. The 5-year patency rate for
popliteal arteries for the series from 1975 to 1985 was
57%. The comparative 5-year tibial/peroneal bypass graft
(with or without dAVF) patency rates for the decade from
1975 to 1985 were: tibial, 32%; and peroneal, 34% with-
out dAVF. The results of the decade from 1990 to 2000
were significantly improved as compared with those results
that were obtained during the decade from 1975 to 1985
for both the popliteals and the crurals (P < .05). The
cumulative limb salvage rates for the two series at 5 years
also showed an impressive improvement of 80% versus
73% for popliteal arteries (P < .05) and 65% versus 58% for
crurals (P < .05). The cumulative actual palliation data are
predictably depressed because of combined failure end-
points (graft failure, amputation, and death). There were
no statistically significant differences in a comparison of
the patency rates as a function of runoff in popliteal recon-
structions, above-knee or below-knee positions, presence
or absence of diabetes, and indications for surgery.
Complications. Thrombosis was the major mechanism
for graft failure and accounted for the major decline in
cumulative patency and limb salvage rates for the entire
series. Perioperative (<1 month) thrombosis and reoperation
for popliteal arteries for the decade from 1990 to 2000 was
5% and for the crurals was 10%, which was a significant
Fig 3. Indications for lower limb revascularization (1990 to
2000).
Fig 4. Comparative cumulative graft patency rates for popliteal
reconstuctions with use of umbilical vein grafts during decades
from 1975 to 1985 (bold lines) and from 1990 to 2000 (light
lines and italics). Difference in curves was statistically significant
in comparison of decades with log-rank test (P < .05). UV,
Umbilical vein graft; Pop, popliteal; SE, standard error.
improvement over the first decade experience when compa-
rable thrombosis and reoperative rates were 11% and 22%,
respectively. Thrombolysis was performed during the decade
from 1990 to 2000 in 27 UVg cases, with lysis achieved in
23 cases (85%) and limb salvage in 20 cases (74%). These
results compare favorably with the first decade experience in
which streptokinase lysis was attempted in 38 cases, with
occluded popliteal grafts being patent at discharge in 60%
versus only 25% for the crural reconstructions.
Nonthrombotic failure occurred in two crural cases
(0.7%) and in no popliteal cases. These results compared
favorably with a 5% nonthrombotic failure rate that
occurred during the decade from 1975 to 1985 (Table
III). We believe that this improvement may be one of the
factors responsible for the improved limb salvage rates
noted in the current decade.
Aside from thrombotic and nonthrombotic events,
other complications included infection, stenosis, dissection,
and pseudoaneurysm formation (Table III). Infection
occurred in nine cases (3%) and always in patients who had
undergone two or more procedures. The removal of the
entire graft was necessary in all cases and eventually resulted
in limb amputation. Stenosis occurred at the distal anasto-
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mosis in three grafts (1%), in the proximal anastomosis in
one and in the midportion of another. The latter was inex-
plicable in that intimal hyperplasia has, to this point, never
been noted in the main body of the graft. When intimal
hyperplasia does occur, it is at the anastomotic areas and
represents pannus ingrowth from the native artery.
Presumably, the midgraft stenosis occurred as a result of
localized intramural dissection or hematoma. Percutaneous
balloon angioplasty was successful in three of the stenosis
cases; direct surgery and patching were performed in the
remaining two. There was one pseudoaneurysm in this
series that needed interposition grafting and one case of dis-
section that was noted during surgery and also corrected
with interposition grafting. Both of these cases may have
been the result of flow surface defects. Overall, the com-
parison of these complications between the two decades
showed no change in their low incidence rates.
Most impressive however, were the findings with respect
to biodegradation and aneurysm formation. The original
series had shown a 2.9% requirement for aneurysm surgery
after 5 years with an overall incidence rate of biodegradation
of 57% (36% aneurysms, 21% dilatation).15,22 The current
series has to date shown no such events.
Fig 5. Comparative cumulative graft patency rates for crural
reconstuctions with use of umbilical vein graft during decades
from 1975 to 1985 (bold lines) and from 1990 to 2000 (light
lines and italics). Differences between curves were statistically
significant (P < .05). UV, Umbilical vein graft; SE, standard error.
Fig 6. Comparative cumulative limb salvage rates for popliteal
and crural reconstuctions with use of umbilical vein graft during
decades from 1975 to 1985 (bold lines) and from 1990 to 2000
(light lines and italics). Differences between any curves were not
statistically significant. UV, Umbilical vein graft; Pop, popliteal;
SE, standard error.
Table II. Secondary cumulative patency and cumulative palliation rates for umbilical vein grafts (1990 to 2000)
Popliteal Crural Total
Interval (years) No. CPR ± SE No. CPR ± SE No. CAP ± SE
1 115 89.6 ± 3.0 168 82.5 ± 3.1 249 79.6 ± 2.6
2 86 85.1 ± 3.6 114 74.7 ± 3.6 182 67.8 ± 3.1
3 67 81.0 ± 4.1 86 66.1 ± 4.2 144 52.9 ± 3.4
4 56 77.8 ± 4.5 62 62.6 ± 4.4 98 47.4 ± 3.5
5 44 71.4 ± 5.5 47 56.0 ± 5.1 68 32.8 ± 3.8
6 26 67.5 ± 6.4 25 46.7 ± 6.5 25 25.3 ± 4.2
CPR, Cumulative patency rate; SE, standard error; CAP, cumulative actual palliation.
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DISCUSSION
This series represents a continuation of the first decade
of experience with UVg of the author and his colleagues.15
Beginning in 1990, a number of noteworthy events
occurred, the most important of which was the change in
the manufacturing process and the improvement in quality
control before distribution. With accumulating experience,
better patient section, routine use of the dAVF with crural
reconstructions, and the reintroduction of the tourniquet
have clearly contributed to improved patency and durabil-
ity of reconstructions with UVg.16,19,23
The decrease in the nonthrombotic failure rate in the
current decade (1.1% versus 5.0%) is also contributory.
Since the first 10-year report, the number of UVg recon-
structions performed in our institution has significantly
decreased. This represents our commitment to the use of
autologous vein. Nevertheless, approximately 20% to 30%
of our cases still require alternative graft materials. This
number reflects the fact that we are often referred cases
from other institutions in which saphenous veins were
used and are no longer available. The data presented
herein and the results with regard to graft patency and
limb salvage rates reflect what we believe to be satisfactory
outcomes and support our thesis for the use of the UVg as
the primary alternative to autologous vein.
Studies on the comparative performances of alterna-
tives to autologous saphenous vein are distressingly lack-
ing. Those randomized prospective studies that do exist
are dated or designflawed or generally have only consid-
ered a single alternative, thus failing to respond to the
query of a “best” alternative in contradistinction to an
“acceptable” alternative.24,25 The Swedish,10 Dutch,11
and English12 studies published in the 1980s, although
they did show superiority of UVg as compared with poly-
tetrafluoroethylene grafts, consisted mostly of bypass
grafts in the above-knee position, dealt with the original
version of the UVg, and lacked standardization. The
recently published study by Johnson and Lee14 suffers
from similar flaws. Our studies, although extensive in
detail, have been both retrospective and prospective and
they lack randomization but do represent a single
group/hospital experience. Clearly, the challenge to the
vascular community is to develop a multihospital, ran-
domized prospective study with guidelines that will permit
the study of two or more materials (biologic and polymer)
in infrageniculate positions. We also believe that adjuncts,
such as the dAVF, should be included as arms of these
studies.19,26,27
The patency rates that were reported in this study for
popliteal and crural reconstructions are significantly better
than those rates reported in the first decade report.15 This
clear trend of improvement is multifactorial, primarily on
the basis of changes in manufacturing, quality control, and
improved technical aspects in the performance of these
operations. Nonetheless, the results of autologous saphe-
nous vein are still superior as long as there is availability
and adequacy. On the other hand, alternative autologous
veins, such as arm and lesser saphenous veins, have gener-
ally not performed as well as the saphenous vein. Several
authors who used autologous vein other than the greater
saphenous vein as their preferential alternative material
have reported patency rates that ranged from 75% (pri-
mary) to 90% (secondary) for popliteal reconstructions
and 60% (primary) to 65% (secondary) for infrapopliteal
reconstructions at 2 years.28 Other investigators have
reported ranges of 46% to 58% (primary) and 58% to 85%
(secondary) at 2 years for all lower limb bypass grafting
procedures with arm veins.29-31 At 5 years, Donaldson,
Whittemore, and Mannick32 reported a non–greater
saphenous vein patency rate of 49% for all infrainguinal
procedures. In that we achieved 5-year UVg secondary
patency rates of 71% for popliteals and 56% for crurals, it
is clear that UVg not only provided comparable and sub-
sequent superior patency rates but had the decided advan-
tage of simplicity and decreased operative time as
compared with the use of alternative autologous vein. The
“all autogenous policy” needs to be revisited.
There has been considerable concern expressed by sur-
geons regarding the devastating effects of biodegradation
when biological grafts are used for revascularization. Most
surgeons attribute this to antigenicity of the graft, as has
been shown with the bovine heterograft.9 This is not clear
for UVg because the glutaraldehyde molecule is better
able to mask histocompatibility antigen sites with effective
cross-linking than are other agents that were previously
used. The possibility for the leaching of glutaraldehyde
over time and, as a consequence, the loss or reversal of
cross-linkage sites may be one of the possible mechanisms
for delayed biodegradation aside from material fatigue or
corrosion.33 Speer et al34 have also suggested that leached
glutaraldehyde can induce adverse cellular effects that con-
sist in vitro of cytotoxic effects on fibroblasts and in vivo
Table III. Nonthrombotic complications of umbilical vein grafts (1990 to 2000)
Group Popliteal Crural Total Old series (1975 to 1985)
No. of grafts 109 174 283 907
Failure without thrombosis 0 2 2 (0.7%) 49 (5.0%)
Infection 1 8 9 (3.2%) 39 (4.3%)
Stenosis 2 3 5 (1.8%) 19 (2.1%)
Dissection 0 1 1 (0.4%) 1 (0.4%)
Pseudoaneurysm 1 0 1 (0.4%) 13 (1.4%)
Aneurysm (surgical repair) 0 0 0 26 (2.9%)
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of foreign body giant cell reaction to glutaraldehyde-
tanned sponge bioimplants. In our early series, there was
indeed a greater than 50% incidence rate of this phenom-
enon occurring after 5 years of implantation, but this was
associated with a low requirement for operative interven-
tion.15 Graft replacement was shown to be necessary in
only 6% of the cases in which graft patency had been main-
tained for 5 or more years. In fact, there were few cases of
biodegradation with aneurysm during the first 5 years of
the follow-up period and, when this did occur, it was in
patients with aneurysm disease. In the decade from 1990
to 2000 that was reported herein, we have noted the total
absence of biodegradation and aneurysm formation. This
is in concert with a rigorous surveillance protocol per-
formed with duplex scan sonography. We attribute this
phenomenon to improved manufacturing processes and
quality control before distribution. If, in fact, little or no
glutaraldehyde is leached, retention of cross-linkages and,
as a consequence, graft architecture could account for
these new and important observations. It is possible that
future biodegradation will still occur, but clearly this will
be at an impressively decreased incidence rate and remote
from the date of surgery.
The UVg is now in its third decade of clinical use and
can be a useful alternative to the saphenous vein if surgeons
will recognize the need for appropriate case selection and
acquire the techniques requisite for success. This includes
the use of tourniquets, dAVF for crural bypass grafting,
and postoperative anticoagulation therapy. Surveillance of
these grafts is essential and can, with appropriate early
intervention, aid in the avoidance of thrombotic events or
other forms of failure. Skepticism expressed by some sur-
geons is in fact rarely on the basis of personal experience
but is more so on an emotional response relating to the
failure of the original bovine heterograft and other negative
experiences with biologic materials. An appreciation of
aldehyde chemistry, such as the nature and extent of amine
linkages and the potential for the reversal of these bonds,
and an understanding of the manufacturing process should
lead surgeons to better analyze and appreciate the results
currently possible and available with the UVg. We all need
to be vigilant against unfounded repetitive activity that
masquerades as scholarship and recognize that the greatest
“obstacle to discovery” is the “illusion of knowledge”.35
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Dr Thomas M. Bergamini (Louisville, Ky). This report rep-
resents one of the largest and longest experience with the use of
human umbilical cord vein graft in the world. Dr Dardik and his
coauthors deserve tremendous credit for their devotion to the
study of this alternative conduit.
Numerous randomized, prospective studies have shown
human umbilical cord vein graft to be superior to other alterna-
tive conduits for femoropopliteal bypass. This study focuses on
femoral crural bypass. The improvement in the results in this
study are multifactorial, as they have done several things differ-
ently. The manufacturing process has changed, which has led to a
decrease in graft dilatation and aneurysm formation with an aver-
age follow-up of 3 years. Longer follow-up is necessary as the
time interval in which graft dilatations and aneurysms occurred in
their prior decade of experience was more than 5 years.
Also, they have had a change in patient selection in the cur-
rent series, avoiding sequential bypasses and bypasses to the tri-
furcation vessels.
I have the following two questions for you. 
You do state that the more remote the distal anastomosis, the
poorer your results. What is an acceptable outflow artery score,
including the diameter, patency length, stenosis and pedal arch
patency? Is bypass to an inframalleolar vessel at the plantar artery
or dorsalis pedis artery acceptable?
Second, We have learned that postoperative surveillance of in
situ and reverse saphenous vein bypasses significantly improves
graft patency and limb salvage as compared to clinical follow-up
alone. Has the institution of a graft surveillance protocol in your
current decade of experience improved the long-term graft
patency and limb salvage, allowing the detection and correction
of the failing grafts as compared to your historical control study
that had clinical follow-up only? What is the mechanism of human
umbilical cord vein graft failure that you’ve learned with the insti-
tution of your surveillance protocol?
Dr Kurt Wengerter. The first question relates to the question
of which outflow tract we use for the bypass graft or which one we
avoid. We do not use pedal vessels, that is the main restriction we
have. The size of the vessel usually doesn’t come into play, although
certainly we see more failures with very small diseased vessels. The
reason for the fistula is to help the outflow of these vessels. We will
go down to the ankle but in general not into the foot.
You asked about the follow-up procedure. We follow these
procedures, as we do with vein grafts, but clearly the mechanism
of failure is often different from veins. The problems generally do
not develop within the graft itself. Most of the problems occur
from possible defects at anastomosis or progressive disease occur-
ring in the outflow tract. Most of the problems can be detected
at the time of surgery because we always perform duplex scans at
that time. However, outflow tract problems are the most com-
mon cause of graft failure, aside from the patient’s own coagula-
tion tendencies, which may reduce patency of the graft as well.
Dr Harry R. Schanzer (New York, NY). I observed an
improvement of about 10% between the first series and the late
series that I don’t think can be explained by modifications in the
graft alone. What are the factors that you think may explain this
improvement? I’m sure that you have done distal AV fistula more
frequently now. You are doing duplex surveillance at the time of
surgery. I don’t know if you were doing them before. Can you
expand on that?
Dr Wengerter. Well, most of the changes were gradual, and
that’s why we included the transition period. We have seen
improvements in all aspects of patency and limb salvage. We feel
that the dAVF is extremely important. It was not used routinely
in the first group. When it was used in the first group, it was only
used in the very worst cases and it tended to give the appearance
that the dAVF was associated with a poorer outcome. In the sec-
ond group it has been adopted across the board for any outflow
artery in the crural system. The outflow volume flow rate
increases several fold with the fistula and it’s important to make
sure the fistula is constructed properly.
Another factor, we believe, is the production of the grafts. Since
1990 we have had a new manufacturer, and we think the quality con-
trol is better. We think this is the reason we’re not seeing aneurysm
formation and dilatation. I’ve been at Englewood for 5 years now,
and I have not seen an aneurysm myself in these grafts. In fact, I did-
n’t see the prior ones because at that time I was at Montefiore not
using the graft. But I can attest to the great difference that has
occurred. We think that’s related to the manufacturing.
Duplex scanning intraoperatively has been done for quite a
number of years. We think it’s extremely important for giving the
surgeon feedback as to his technique and we find periodically
problems with the graft that can be fixed, not only at the outflow
tract but at the inflow tract as well, which may not be seen on
angiograms.
Dr Kenneth C. Grant (Charlottetown, Prince Edward Island,
Canada). Long grafts, prosthetic grafts to AV fistulas for limb
ischemia as a last resort have seemed to worked well for a short
time, and then after a year or 2—sometimes that time is enough—
but after a year or 2 they close down, mainly because of the fast
flow through the fistula, the hyperplastic response to fast flow. I
gather that hasn’t been an issue with the umbilical vein graft?
Dr Wengerter. We have not seen the hyperplasia as much as
I’ve seen it in the past with PTFE grafts. Compliance is different
with the UV graft; it’s much better than PTFE, even long term,
and we think that is part of the reason. The fistulas don’t all stay
open long term, and many of the grafts will stay open even after
the fistula is closed. So it’s not always 100% dependent on the fis-
tula flow. We have not seen the hyperplastic changes occur as
much as we see with arm vein fistulas or with other prosthetic
outflow tracts. And we think that’s part of the reason for the
enhanced patency. We have previously reported annual attrition
rates of dAVFs ranging from 13% to 26%.
DISCUSSION
